These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10992997)
1. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial]. Szucs TD; Berger K; März W; Schäfer JR Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study]. Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J; Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242 [TBL] [Abstract][Full Text] [Related]
5. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease. Glasziou PP; Simes RJ; Hall J; Donaldson C Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428 [TBL] [Abstract][Full Text] [Related]
6. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients]. Berger K; Klose G; Szucs TD Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Muls E; Van Ganse E; Closon MC Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184 [TBL] [Abstract][Full Text] [Related]
9. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of statins. Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919 [TBL] [Abstract][Full Text] [Related]
11. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. Coukell AJ; Wilde MI Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462 [TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease) Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335 [TBL] [Abstract][Full Text] [Related]
13. Pravastatin and coronary heart disease. Bloom JM N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831 [No Abstract] [Full Text] [Related]
14. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease]. Sato S; Matsushita Y; Kobayashi T; Awata N Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898 [TBL] [Abstract][Full Text] [Related]
15. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. Marschner IC; Colquhoun D; Simes RJ; Glasziou P; Harris P; Singh BB; Friedlander D; White H; Thompson P; Tonkin A; J Am Coll Cardiol; 2001 Jul; 38(1):56-63. PubMed ID: 11451296 [TBL] [Abstract][Full Text] [Related]
16. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541 [TBL] [Abstract][Full Text] [Related]
17. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?]. Klose G Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302 [No Abstract] [Full Text] [Related]
18. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275 [TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Tonkin AM; Colquhoun D; Emberson J; Hague W; Keech A; Lane G; MacMahon S; Shaw J; Simes RJ; Thompson PL; White HD; Hunt D Lancet; 2000 Dec; 356(9245):1871-5. PubMed ID: 11130382 [TBL] [Abstract][Full Text] [Related]
20. A clinical focus on statins. Auer J; Eber B Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]